The epithelial cell adhesion molecule (EpCAM) is an integral transmembrane protein that is frequently overexpressed in embryonic stem cells, tissue progenitors, carcinomas and cancer-initiating cells. In cancer cells, expression of EpCAM is associated with enhanced proliferation and upregulation of target genes including c-myc. However, the exact molecular mechanisms underlying the observed EpCAM-dependent cell proliferation remained unexplored. Here, we show that EpCAM directly affects cell cycle progression via its capacity to regulate the expression of cyclin D1 at the transcriptional level and depending on the direct interaction partner FHL2 (four-and-a-half LIM domains protein 2). As a result, downstream events such as phosphorylation of the retinoblastoma protein (Rb) and expression of cyclins E and A are similarly affected. In vivo, EpCAM expression strength and pattern are both positively correlated with the proliferation marker Ki67, high expression and nuclear localisation of cyclin D1, and Rb phosphorylation. Thus, EpCAM enhances cell cycle progression via the classical cyclin-regulated pathway.
INTRODUCTION
The epithelial cell adhesion molecule (EpCAM) is a transmembrane protein with dual function as it is implicated in cell adhesion and mitogenic signalling. 1 EpCAM is expressed in the basal membrane layers of simple squamous epithelia, 2 and is overexpressed in various carcinomas 3 and in tumour-initiating cells (also termed cancer stem cells). 4, 5 Recent publications uncovered the expression and tight correlation of EpCAM with the pluripotent and proliferative phenotype of human and murine embryonic stem cells. 6 --8 Elucidation of the mechanisms and compounds involved in EpCAM-mediated signalling provided a solid rationale for the observed expression patterns and potential functions of EpCAM in health and disease. 1 One route of activation of EpCAM signalling relies on homophilic aggregation of EpCAM on opposing cells and results in a regulated intramembrane proteolysis. 9 Initially, the extracellular domain termed EpEX is shed as an ectodomain, which can bind to intact EpCAM molecules itself to foster regulated intramembrane proteolysis. Ectodomain shedding is a prerequisite for the second step of activation that consists of an intramembrane cleavage of the remaining C-terminal fragment by g-secretase complexes containing presenilin-2 as a catalytic subunit. 10 Upon intramembrane cleavage, the intracellular domain termed EpICD is released as a remarkably small 5-kDa protein, which is complexed with the adaptor protein FHL2 (four-and-ahalf LIM domains protein 2) and b-catenin in human carcinoma cells. 10 EpICD-containing multiprotein complexes translocate into the nucleus and, upon interaction with the transcription factor Lef-1, are recruited to DNA to regulate gene transcription and subsequently cell proliferation. In embryonic stem cells, EpICD is directed to promoters of pluripotency genes such as oct4, nanog, c-myc, sox2 and klf4, and may thereby maintain the proliferative and undifferentiated state of embryonic stem cells. 8 
Apparently, this feature of EpCAM is also important during reprogramming of differentiated cells into induced pluripotent stem cells (iPS).
EpCAM and E-cadherin are markers of fully reprogrammed iPS, 11 and EpCAM/EpICD foster the generation of iPS when coexpressed with classical iPS genes. 12 In human cells, treatment with EpCAMspecific antibody G8.8 primarily altered the expression of genes involved in cell proliferation and cell cycle regulation. 13 Although c-Myc, as a target of EpCAM, can explain some of the cellular effects of EpCAM, the actual mechanism behind EpCAM-mediated proliferation remained unexplored. It is still unclear whether EpCAM can directly activate components of the cell cycle machinery or if EpCAM-mediated proliferation is a secondary effect, for example, through repression of apoptosis, elevation of cell metabolism or interruption of antiproliferative signals.
We show here that EpCAM controls cell cycle progression via the regulation of the key player cyclin D1 at the transcriptional level. As a result, downstream effects such as phosphorylation of retinoblastoma protein (Rb) and cell cycle progression are inhibited upon EpCAM downregulation and cells accumulated in G1 phase. Hence, EpCAM directly affects cell cycle regulation via the classical cyclin-regulated pathway.
RESULTS

Repression of EpCAM expression correlates with loss of cell proliferation and delayed cell cycle progression
The de novo expression of EpCAM results in improved cell proliferation in HEK293 cells, especially under conditions of cellular stress such as growth factor withdrawal. 14 Based on these findings, we tested the effects of EpCAM or FHL2 downregulation on FaDu hypopharynx carcinoma cells. FHL2 is a direct interacting partner of EpICD, which is required for growth-promoting properties of EpCAM in HEK293 cells. 10 FaDu cells were transiently transfected with small interfering RNA (siRNA) oligonucleotides specific for EpCAM or FHL2. As a control, cells were transfected with a commercially available siRNA, which has no known targets in the human genome (control siRNA). Reduction of EpCAM total protein expression at the plasma membrane after treatment of cells with EpCAM-specific siRNA is exemplified in Supplementary   Figures S1A and B . EpCAM-and FHL2-specific siRNAs were similarly effective and resulted in knockdown efficiencies of 80% and 70% at the mRNA level and 66% and 70% at the protein level in immunoblots, respectively (Figures 3a and b Figure 1d ). The significance of the observed differences in doubling times was calculated across all three groups of cells under normal and restrictive conditions. All differences observed in Figure 1d were considered highly significant (Figure 1e ), except between cells treated with EpCAM-or FHL2-specific siRNAs. Under restrictive conditions with supplementation of 1% FCS only, cells treated with EpCAM or FHL2 siRNA did not significantly differ in doubling times. Under permissive conditions (10% FCS), differences in doubling times between these two cell groups were considered significant (0.03; Figure 1e ). Hence, knockdown of EpCAM and FHL2 similarly enhanced doubling times of FaDu cells as compared with control-treated cells.
The repartition of cells in the different phases of the cell cycle was assessed in dependency of the expression of EpCAM and FHL2 in FaDu carcinoma cells. Cells were transiently transfected with control, EpCAM or FHL2 siRNAs, and cell cycle distribution was monitored upon staining with propidium iodide. Inhibition of EpCAM or FHL2 expression led to a reproducible accumulation in G1 phase, associated with significantly decreased percentages of cells in S phase and G2 phase (Figure 2 ). Effects of EpCAM and FHL2 inhibition on proliferation and cell cycle progression were similar in their amplitude.
EpCAM regulates the transcription of the cyclin D1 gene In order to test if EpCAM affects progression through the cell cycle directly or indirectly, the expression of the essential regulator cyclin D1 was monitored in dependency of EpCAM and FHL2. FaDu cells were transiently transfected with control, EpCAM or FHL2 siRNAs, and levels of EpCAM and FHL2 visualised in immunoblots. EpCAM and FHL2 siRNA oligonucleotides induced reductions of mRNA and protein amounts after 48 h in the range of 65 --80% (Figures 3a and b) . Messenger RNA levels of cyclin D1 were addressed upon quantitative real-time PCR in parallel. After knockdown of EpCAM or FHL2, cyclin D1 mRNA levels were reduced by 75% and 60%, respectively (Figure 3b ). Similar levels of reduction of cyclin D1 were observed at the protein level, confirming results of quantitative PCR (Figure 3c ). Comparable experiments were performed with A549 lung carcinoma cells. Reduction of EpCAM or FHL2 expression upon treatment of A549 with specific siRNA resulted in an average 55% decrease in cell numbers after 72 h of treatment and in 50% decrease in cyclin D1 mRNA levels (data not shown).
The cyclin D1 gene is regulated via the canonical b-catenin/Lef-1 pathway, and Lef-1 consensus sequences within the promoter have been identified. 15 Lef-1 consensus sequences originating from the cyclin D1 promoter (probes) were used to perform electromobility shift assays (EMSAs) with nuclear and cytoplasmic extracts of FaDu cells. Two major protein/DNA complexes (I and II) could be detected after incubation of radioactively labelled probes with FaDu nuclear extracts (Figure 3d, left panel) . The specificity of protein/DNA complexes for Lef-1 sequences was addressed upon competition experiments with unlabelled oligonucleotides representing the Lef-1 consensus sequence of the cyclin D1 promoter (Top) or a mutated version to which Lef-1 no longer binds (Fop). Titration of cold Top-oligonucleotides but to a far lesser extent of Fop-oligonucleotides resulted in a gradual decrease of both major protein/DNA complexes ( Figure 3d , left panel). Upon biochemical and genetic approaches, EpICD was described as a component of a nuclear (but not cytoplasmic) protein complex involved in the formation of protein/DNA complex II. 10 Hence, processing of EpCAM to generate the signalling moiety EpICD via regulated intramembrane proteolysis was hampered with presenilin-specific inhibitor N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine tbutyl ester (DAPT). Nuclear and cytoplasmic fractions of treated and untreated cells were prepared and subjected to EMSA with cyclin D1 probes in duplicates. Formation of protein/DNA complex II was exclusively seen with nuclear but not cytoplasmic extracts (Figure 3d , right panel), whereas complex I was formed in both cellular compartments. However, formation of complex I was stronger in the nuclear fraction. Importantly, formation of complex II in nuclear extracts was totally abrogated upon treatment of FaDu cells with the presenilin-specific inhibitor DAPT, whereas formation of complex I was only weakly affected ( Figure 3d , right panel). Incubation of nuclear extracts with anti-EpICD antibodies did not result in a supershift of protein/DNA complexes, but rather hampered the formation of protein/DNA complexes if preincubated with nuclear extracts. Pre-incubation of nuclear extracts with EpICD-specific antibodies overnight at 41C resulted in a 40--52% reduction of signal intensity, which was in the same range as samples pre-incubated with Lef-1-or b-catenin-specific antibodies for 30 min at room temperature (Supplementary Figure 2A) . These data suggested that EpICD is potentially incorporated in both complexes I and II, and pre-incubation with EpICD-specific antibody inhibits DNA binding of the complexes. However, EpICD appears essential for the generation of complex II, while being dispensable for complex I.
Alternatively, to address the requirement for EpICD during the formation of protein/DNA complexes at the cyclin D1 promoter, we used HEK293 cells, which are negative for EpCAM but are responsive to EpCAM-mediated proliferation.
14 Nuclear extracts of HEK293 cells allow for the formation of protein/DNA complex I but not II (Supplementary Figure 2B) . HEK293 cells were transiently transfected with expression plasmid for EpICD-YFP, and nuclear extracts of transient transfectants were incubated with labelled cyclin D1 promoter probes to perform EMSAs. Alternatively, a synthetic peptide composed of the 26 amino acids of EpICD was spiked into nuclear extracts of untransfected HEK293 cells and used similarly. Reconstitution of protein/DNA complex II and a moderate increase in the formation of complex I was detected after expression of EpICD-YFP (Supplementary Figure 2B) . Supplementation of synthetic EpICD was not functional, which is in line with its rapid and quantitative degradation in cell lysates (data not shown). Thus, EpICD is essential for the formation of nuclear complex II at Lef consensus sites of the cyclin D1 promoter.
EpCAM affects Rb phosphorylation, cyclin A and E2 transcription Cyclin D1 is the essential cofactor of cyclin-dependent kinases (CDKs) 4 and 6, which upon activation phosphorylate retinoblastoma protein (pRb), resulting in the release of the E2F transcription factor and subsequent transcription of cyclins A and E, which are involved in the progression through cell cycle. 16 Based on the regulation of cyclin D1 by EpCAM at the transcriptional level, we next analysed the effects of EpCAM and FHL2 on the phosphorylation status of Rb at serine residue 780, which represents a requirement for S-phase transition 17 and depends on cyclin D1. 18 FaDu cells were transiently transfected with EpCAM-or FHL2-specific siRNA and harvested 24, 48 and 72 h after transfection. Lysates of these cells were assayed for Rb phosphorylation using the phospho-Rb serine 780 kit. For a control, total levels of Rb, actin and EpCAM were assessed in parallel. Reduction of EpCAM or FHL2 proteins levels resulted in concurrent reduction of phosphorylation of serine 780 within pRb, but not in the reduction of overall Rb levels ( Figure 4a) .
Release of E2F upon phosphorylation of Rb is a prerequisite for the induction of further regulators of cell cycle transition such as cyclins A and E. Samples of FaDu cells subjected to treatment with EpCAM and FHL2 siRNAs were next tested for levels of cyclin A and E2 mRNAs and proteins. Reduction of EpCAM mRNA levels by 75% resulted in mean 30% and 40% reduction of cyclin A and E2 mRNAs, respectively ( knockdown induced 40% and 55% reduction of cyclin A and E protein levels, respectively. FHL2 knockdown resulted in 25% and 60% reduction of cyclin A and E protein levels, respectively (Figure 4c ).
EpICD induces cyclin D1 transcription and expression
The observed reductions of cell proliferation, cyclin D1, cyclin A Figure 1C) . (Figure 5a ). Expression of EpICD-YFP with control siRNA disclosed proliferative effects of EpICD in FaDu cells and resulted in a mean 30% increase in cell numbers (Figure 5a) . Accordingly, cells treated with control siRNA and ectopically expressing EpICD-YFP displayed the shortest doubling times (10.18 ± 0.24 h). Cells treated with control siRNA and expressing YFP were similar to cells treated with EpCAM siRNA but expressing EpICD-YFP (11.06±0.06 and 11.30±0.13 h), whereas cells treated with EpCAM siRNA and expressing YFP had the longest doubling times (13.98 ± 0.18 h) (Figure 5a, first table) . The significance of the observed differences was calculated with paired Student's t-test, where values from cells transfected with YFP and control siRNA served as a reference (Figure 5a, second table) . According to these calculations, EpICD induced a significant increase in cell number, whereas EpCAM knockdown resulted in significant decrease of cell number, which was rescued upon EpICD co-transfection (difference to YFP-Csi considered not significant). Hence, EpICD-YFP enhances proliferation of FaDu cells and can complement for the lack of wild-type EpCAM.
Samples of the abovementioned siRNA-treated cells were studied for expression levels of cyclin D1 mRNA transcripts and protein. For comparison, samples of FaDu cells treated with control siRNA and ectopically expressing YFP were set to one and served as a reference. EpICD-YFP expression induced a 2.09-fold increase in cyclin D1 mRNA transcript under these conditions (Figure 5b ), which was paralleled by a substantial induction of cyclin D1 protein expression (Figure 5c ). Knockdown of EpCAM in FaDu cells resulted in a 44% decrease in cyclin D1 transcript and protein levels, which could be complemented upon overexpression of EpICD-YFP, both at the mRNA transcript and protein expression levels (Figures 5b and c) .
EpCAM, Ki67, cyclin D1 expression and Rb phosphorylation status correlate in vivo The in vitro experiments disclosed a tight correlation between the expression of EpCAM and EpICD-YFP with transcription and expression of cyclin D1, and phosphorylation of Rb protein. In order to validate these data in vivo, serial sections of primary samples of normal mucosa and head and neck carcinomas were immunostained with antibodies specific for EpCAM, Ki67, cyclin D1, Rb and phospho-Rb. Seven cases also included tumour proximal areas of microscopically normal mucosa characterised by regular stratification and no morphological signs of transformation. In normal tissue, EpCAM was primarily expressed in cells of the first suprabasal membrane layers. Expression patterns tightly correlated with cyclin D1 and Ki67 expression (Figure 6a , left two panels and Supplementary Figure S3) . Magnifications of normal mucosas and of head and neck carcinomas are shown in Figure 6b and comprised cellular infiltrate, tumour cells and stroma. In normal mucosas, Ki67 was primarily detected in nuclei of cells of the first and second suprabasal membrane layers, whereas Rb was detected more broadly in the suprabasal layers, but predominantly in a serine 780 non-phosphorylated form (Figure 6b , upper panels). Staining intensities of EpCAM, cyclin D1 and ki67 in normal mucosas are given in Supplementary Table S1 . It must be noted that staining intensities relate to the first two to three suprabasal cell layers only. Remaining epithelial cells of normal mucosas did generally not express EpCAM, cyclin D1 or ki67 (Supplementary Table S1 ). Autologous head and neck carcinomas (n ¼ 11) were characterised by strong overexpression of EpCAM and cyclin D1 throughout or in greatest parts of the tumour mass, with cyclin D1 displaying a primarily nuclear localisation (Figure 6a , right two panels and Supplementary Figure S3 ). Staining intensities of EpCAM, cyclin D1 and ki67 are given in Supplementary Table S1 . Tumour areas consistently expressed high levels of EpCAM, cyclin D1 and Ki67 and phosphorylated Rb with coincident expression patterns within the tumour mass (Figure 6b and Supplementary Figure S3 ).
DISCUSSION
First descriptions of a correlation of EpCAM with a proliferative and de-differentiated state of epithelia date back to the mid 1990s, when Litvinov et al. 19 and Schon et al. 20 analysed cervical intraepithelial neoplasia and transformed epithelia, respectively. EpCAM expression was correlated with the proliferation marker Ki-67 at the expression level in primary cervical intraepithelial neoplasia samples and was expressed to lesser degree in welldifferentiated cervical intraepithelial neoplasia cells. 19 In spontaneously transformed keratinocytes, high expression of EpCAM was associated with enhanced cell proliferation and EpCAM levels decreased with cell ageing. 20 Subsequent work demonstrated oncogenic and proliferation supporting capacities of EpCAM, along with its ability to induce transcription of the c-Myc oncogene.
14,21 Activation of gene transcription by EpCAM relies on regulated intramembrane proteolysis of the molecule by tumour necrosis factor-a-converting enzyme and a g-secretase complex containing presenilin 2 as a catalytic subunit. 10 The resulting signalling moiety EpICD translocates into the nucleus, contacts DNA at Lef-1 consensus sites, and as such regulates transcription of genes primarily involved in proliferation and metabolism. 10, 13, 22 However, it remained open whether these effects of EpCAM, which are in support of proliferation and an undifferentiated pluripotent phenotype, 1 are direct or rather secondary effects resulting from the induction of target genes with mitogenic activities. In the present study, we demonstrate that EpCAM regulates initial steps in the transition of cells through the cell cycle via its ability to induce the transcription of cyclin D1. Cyclin D1 is the first cyclin required for entry in the cell cycle, as it is essential in the transition from G1 phase to S phase as cofactor for CDK4 and CDK6. In cooperation, CDK4/6 associated with cyclin D1 dictate the phosphorylation status of the tumour-suppressor protein Rb. Upon binding to cyclin D1, CDK4 and CDK6 become catalytically active and licensed to phosphorylate Rb and, thereby, induce the release of the transcription factor E2F from sequestration by Rb. EpCAM regulates the transcription and expression of cyclin D1, and consequently the phosphorylation of Rb was affected by variations in levels of EpCAM. Knockdown of EpCAM induced a decreased cell proliferation, decreased expression of cyclin D1 and Rb phosphorylation, increase of cells in the G1 phase and proportionally diminished numbers of cells in the S and G2 phases. The signalling moiety of EpCAM, that is EpICD, was able to complement for the lack of EpCAM with respect to cell proliferation and cyclin D1 gene transcription, suggesting that EpCAM affects cell cycle progression via signalling-dependent mechanisms rather than via its cell adhesive properties. This notion is further supported by the fact that inhibition of FHL2 expression has similar effects than the EpCAM knockdown. FHL2 is a direct interacting partner of EpCAM, which is essential for signalling. 10 Owing to its modular structure composed of protein --protein interaction domains (LIM domains), FHL2 can contact various molecules involved in EpCAM signalling including EpCAM itself, 10 b-catenin, tumour necrosis factor-a-converting enzyme and presenilin 2. 23 Interestingly, FHL2 was shown to regulate the expression of cyclin D1 in mouse fibroblasts via its ability to associate with the cyclin D1 promoter at TCF consensus sites. 24 Similar to EpCAM, inhibition of FHL2 expression led to a substantial impairment of cell proliferation and to hypophosphorylation of Rb. 24 Based on these and our findings, we conclude that FHL2 is a central component of the EpCAM signalling pathway, which is mandatory for the transmission of EpCAM signals from the plasma membrane into the nucleus and, more specifically, to target genes such as cyclin D1. Similar functions of FHL2 have been reporter for Rho signalling and are in further support of central functions of FHL2 in cellular signal transduction. 23 However, the sole presence of FHL2, for example in HEK293 cells, was not sufficient to form protein/DNA complex II at the cyclin D1 promoter. Expression and proteolytic activation of EpCAM as seen in carcinoma cells or complementation of HEK293 cells with the pre-cleaved moiety EpICD was mandatory to this end. Nonetheless, FHL2 appears as an essential mediator of EpCAM signalling, most probably because of its ability to interconnect various proteins, including those central to regulated intramembrane proteolysis of EpCAM. As has been shown for EpCAM, FHL2 is overexpressed in vivo in gastric and colon cancers, where its suppression results in the inhibition of carcinogenesis. 25 Similar to EpCAM, 26 FHL2 overexpression in ovarian and breast cancer is a negative prognostic marker. 27, 28 Interestingly, FHL2 is also overexpressed in hepatocellular carcinomas, 29 in which EpCAM is a negative prognostic marker, which marks tumourinitiating cells. 30 Thus, FHL2 and EpCAM are conjointly upregulated in a substantial number of tumour entities, where they might play an important role in promotion of tumour initiation and growth.
At the molecular level, reduced expression of EpCAM or FHL2 further correlated with a reduction of cyclin A and E transcripts. However, this reduction was not quantitatively proportional to the reduction of EpCAM transcripts, as was the case for cyclin D1, and revealed repeatedly inferior to the amplitude of EpCAM knockdown. Hence, these data suggest an indirect regulation of cyclins A and E by EpCAM, very likely through hyperphosphorylation of Rb and ensuing release of E2F, which is a direct inducer of cyclins A and E. 31, 32 Additionally, c-Myc becomes activated by EpCAM 10, 14 and is itself an inducer of cyclins A and E. 33 Thus, EpCAM possibly induces expression of cyclins A and E via an indirect route possibly involving E2F and/or c-Myc. EpCAM was furthermore shown to repress the expression of p53 and p21 during processes of reprogramming of murine embryonic fibroblasts. 12 Although this effect was so far not investigated in tumour cells, EpCAMmediated repression of p53 and p21 might reveal to be another level of regulation of the cell cycle by EpCAM in cancer. In light of the reported induction of genes involved in reprogramming and formation of tumour-initiating cells such as c-myc 14 and pluripotency genes (Oct4, Nanog and KLF4), 6 --8,12 EpCAM apparently acts at several crucial levels of regulation of the cell cycle and pluripotency. It is noteworthy that the positive and negative feedback loops take effect on the expression of EpCAM. These include the upregulation of the epcam gene by Tcf-4, a member of the Wnt-b-catenin signalling pathway. 34 Oppositely, EpCAM expression is repressed by p53, which was reported as a contribution of p53 to the inhibition of invasive growth in breast cancer. 35 Accordingly, loss of p53 resulted in DNA hypomethylation and amplification of the epcam gene. 36 Together with the fact that p53 represses Nanog expression and induces a differentiation programme in embryonic stem cells, 37 these data point toward opposite expressions and functions of p53 and EpCAM in proliferation and differentiation.
EpCAM overexpression was first described in human melanoma and colon cancer. EpICD was preferentially observed in the nucleus of colon carcinoma samples, but not in normal colon mucosa, where EpICD was retained at the plasma membrane. 10 Interestingly, regulation of cyclin D1 expression is fulfilled by b-catenin and Lef-1 in colon carcinoma, 15 both interaction partners present in nuclear complexes comprising EpICD and FHL2. 1, 10 Oligonucleotide sequences used for EMSAs are composed of Lef-1 consensus sites of the cyclin D1 promoter region. Two major protein/DNA complexes were detected in nuclear extracts of EpCAM-positive cells, when incubating with cyclin D1-specific oligonucleotide probes. Both complexes revealed sensitive to increasing concentrations of unlabelled wild type but far less to mutated oligonucleotides. However, primarily the lower migrating protein/DNA complex II was sensitive to treatment of cells with g-secretase inhibitors, which avert EpCAM cleavage, whereas the intensity of complex I only weakly diminished. Additionally, complex II was lacking in EpCAM-negative cells but was reconstituted upon transient overexpression of EpICD. Thus, EpICD appears essential for the formation of complex II, whereas it is dispensable for complex I, although data indicate an integration of EpICD in both complexes. In this context, it should also be noted that EpICD is a highly labile protein, which becomes rapidly and efficiently degraded in cell lysates. This is corroborated by the fact that a synthetic peptide composed of the 26 amino acids of EpICD is not instrumental in driving the formation of protein/DNA complex II in EpCAM-negative cells, when spiked into cell lysates. In line with this finding, EpICD peptide is readily visualised in immunoblots only as a pure synthetic peptide but not after incubation in cell lysates. 9 Molecular mechanisms underlying this efficient degradation are so far unexplored, but are likely involved in the fine-tuning of EpCAM signalling at the level of EpICD stability.
From the data presented, we conclude that EpICD decisively contributes to the formation of one out of two major protein/DNA complexes, which bind to the cyclin D1 promoter. Obviously, these data also suggest additional and EpCAM-independent levels of regulation of cyclin D1 by b-catenin and Lef-1. However, protein/DNA complex I contains proteins already assembled in the cytoplasm and in EpCAM-negative cells (see Figure 3d and Maetzel et al. 10 ), which is not the case for EpICD-containing complexes, and might hence support distinct functions during cyclin D1 regulation. It is conceivable that overexpression and activation of EpCAM signalling directly contributes to the deregulation of cell cycle transitions and to proliferation in colon carcinoma and other tumour entities, through the induction of cyclin D1. Importantly, a correlation of EpCAM with the expression of cyclin D1, Ki67 and the phosphorylation of Rb was detected in primary samples of head and neck carcinomas, strongly suggesting in vivo relevance of our findings. Actually, this type of regulation represents the most direct option to control G1/S transition and thus proliferation, and will have strong impact on tumourigenesis in case of a deregulated activation of EpCAM. Head and neck squamous cell carcinomas are characterised by strong overexpression of EpCAM 38 and cyclin D1. 39 Both EpCAM and cyclin D1 are predictors of an invasive phenotype and poor prognosis of head and neck squamous cell carcinoma patients. 38, 40 These correlations and a relationship between both proteins can now be understood at the molecular level and explain the observed bad prognosis.
MATERIALS AND METHODS
Cell line, cell lines and plasmids
Hypopharynx carcinoma FaDu cells were cultured in Dulbecco's modified Eagle's medium with 1 or 10% fetal calf serum. Transient cell clones were generated by transfection using MATra reagent according to the manufacturer's protocols (IBA GmbH, Gö ttingen, Germany). For rescue experiment, YFP (pEYFP-N1 plasmid) and EpICD-YFP (EpICD complementary DNA cloned in pEYFP-N1 plasmid) plasmids (1 mg each) were cotransfected with the indicated siRNA oligonucleotides.
siRNA transfection 14 Statistical significance was calculated using paired Student's t-test. P-values of o0.05 were considered significant, Pvalues of o0.001 were considered highly significant.
Electromobility shift assays
Nuclear and cytosolic extracts from FaDu cells were prepared according to the manufacturer's protocol (NE-PER; Pierce, Thermo Fisher Scientific Inc., Rockford, IL, USA) and incubated with 32 P-labelled duplex oligonucleotide probes following a published protocol. 10 Where indicated, cells were treated with 10 mM of the g-secretase inhibitor DAPT (Sigma Aldrich Chemie GmbH, Taufkirchen, Germany) or nuclear extracts supplemented with 200 ng synthetic EpICD peptide. Protein-DNA complexes were separated upon native polyacrylamide gel electrophoresis and visualised with X-ray films.
Cell cycle analysis 3 Â 10 5 cells were plated and transfected with control, EpCAM or FHL2 siRNAs. Cells were grown in 10% FCS. Cell cycle distribution was assessed after 2 days using propidium iodide staining. Cell cycle distribution of cells in G1, S and G2/M phases was analysed in a FACScalibur cytometer (Becton Dickinson, Heidelberg, Germany).
Immunoblot analysis
Cells were transiently transfected with control, EpCAM or FHL2 siRNAs, and thereafter lysed in 40 ml of lysis buffer (Tris-buffered saline/1% Triton and Roche protease inhibitors, Roche, Penzberg, Germany). Proteins were separated by 15% sodium dodecyl sulphate --polyacrylamide gel electrophoresis and transferred to a 45-mm nitrocellulose membrane (polyvinylidene fluoride; Millipore GmbH, Schwalbach/Ts, Germany). EpICD, 10 FHL2 (Cell Sciences, Canton, MA, USA) and b-catenin (BD Pharmingen, Heidelberg, Germany) antibodies were used in dilutions of 1:1000 in combination with horseradish peroxidase-coupled secondary antibody (1:5000) and the ECL system (Millipore) as described before. 10 Quantitative real-time PCR Total RNA from transiently transfected cells was isolated using the RNeasy kit (Qiagen Deutschland, Hilden, Germany). First-strand complementary DNA was synthesised using 1 mg of total RNA (DNase treated) in a 20-ml reverse transcriptase reaction mixture (QuantiTect Rev. Transcription Kit; Qiagen). The mRNA regions of GAPDH, EpCAM, FHL2, cyclin D1, cyclin E and cyclin A were amplified using following primers: All real-time PCR reactions were performed in a 10-ml mixture containing 1 ml of complementary DNA, 5 ml of QuantiTect SYBR Green PCR Master Mix and 0.2 mM of each primer at 60 1C. Real-time quantisation was performed using Roche LightCycler -carousel-based system.
Rb protein assay 3 Â 10 5 FaDu cells were plated in six-well plate and transfected with siRNA as described before. At different time points, cells were harvested and lysed in 40 ml of lysis buffer (phosphatase inhibitors were added: 5 mM NaF and 2 mM Na orthovanadate). Proteins were separated using immunoblot analysis described above and antibodies used were human retinoblastoma phosphoserine780 and human retinoblastoma antibody (Phospho Rb-kit; Cell Signalling Company, New England Biolabs GmbH, Frankfurt, Germany).
Human samples and in vivo immunohistochemistry
Samples were obtained from head and neck squamous cell carcinoma patients (n ¼ 11) after informed written consent during routine surgery and in accordance with institutional ethics approval (Ethikkommision der Medizinischen Fakultät der Ludwig-Maximilians-Universität Mü nchen). Seven cases also included tumour proximal areas of microscopically normal mucosa characterised by regular stratification and no morphological signs of transformation. Haematoxylin --eosin-stained cryosections (4 mm) of these samples were reviewed to confirm diagnoses, document areas of squamous carcinoma cells and accordingly areas of normal mucosa. Sections of 4 mm thickness were cut on Superfrost plus slides and subjected to immunohistochemical analysis using the avidin-biotin-PO-Complex method. In brief, consecutive sections were fixed for 5 min at room temperature in aceton, followed by incubation with fresh 3.5% paraformaldehyde for additional 5 min at room temperature. Endogenous peroxidase activity was blocked using 0.3% H 2 O 2 in phosphate-buffered saline for 10 min, followed by overnight incubation at 4 1C with mouse monoclonal antibodies specific for EpCAM (Cell Signaling; 1:2000 dilution), cyclin D1 (DCS Innovative Diagnostik Systeme, Hamburg, Germany, ready-to-use dilution), Ki67 (Dako Diagnostica GmbH, Hamburg, Germany; 1:800 dilution), Rb 4H1 (Cell Signaling; 1:500 dilution) and a rabbit polyclonal antibody for phosphoRb Ser807/811 (Cell Signalling; 1:100 dilution). Thereafter, sequential incubations with biotinylated anti-mouse, respectively anti-rabbit secondary antibody and peroxidase-labelled avidinbiotin complex were conducted (Vector Lab. Inc., Burlingame, CA, USA). Amino-ethyl-carbazole peroxidase substrate was used for the detection of antigen/antibody complexes, generating a red --brown staining. Counterstaining was achieved with haematoxylin (blue). Negative controls were conducted simultaneously using mouse and rabbit isotype control antibody, respectively (Cell Signaling).
